Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Node Negative Breast Cancer Patients.

Next Previous
X
Search
Trial Profile

Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Node Negative Breast Cancer Patients.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nelipepimut-S (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 05 Jun 2013 Status changed from active, no longer recruiting to completed, according to a Galena Biopharma media release.
    • 05 Jun 2013 Results of this trial and SN 33 [Profile 700020465 ] presented at American Society of Clinical Oncologists (ASCO) 2013 Annual Meeting, according to a Galena Biopharma media release.
    • 12 Mar 2013 Data has been presented at the 27th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), according to a Galena Biopharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top